CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is -799.5%, lower than 95% of its Biotechnology peers (median -23.6%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.96BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
3.17xvs all stocks
52-Week Change
-11.39%vs all stocks
Market Capitalization
1.96BUSDvs all stocks (USD)
Enterprise Value
1.99BUSDvs all stocks (USD)
Forward P/E
-6.94xvs Biotechnology peers
Price to Book (MRQ)
160.37xvs Biotechnology peers
Enterprise to EBITDA
-3.83xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-71.98%vs Biotechnology peers
Return on Equity (TTM)
-799.46%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-520.11MUSDvs all stocks (USD)
Net Income (TTM)
-586.84MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-511.40MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-256.22MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-745.38MUSDvs all stocks (USD)
Pre-tax Income
-737.38MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.44MUSDFY2025 · Dec 31, 2025Net Income
-738.82MUSDFY2025 · Dec 31, 2025EBIT
-745.38MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-735.46MUSDFY2025 · Dec 31, 2025Research & Development
635.07MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
110.31MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-738.82MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-617.91MUSDFY2025 · Dec 31, 2025Free Cash Flow
-618.62MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
232.78MUSDFY2025 · Dec 31, 2025Income Tax Paid
133.00KUSDFY2025 · Dec 31, 2025Interest Paid
216.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-738.82MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
9.92MUSDFY2025 · Dec 31, 2025Stock-based Compensation
112.36MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.02MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-6.39MUSDFY2025 · Dec 31, 2025Capital Expenditures
-715.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-266.88MUSDFY2025 · Dec 31, 2025Sale of Investments
570.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
-1.85MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
300.56MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
250.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.89MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
437.28MUSDFY2025 · Dec 31, 2025Shares Outstanding
151.02MSharesUpdated Sep 27, 2026Float Shares
116.57MSharesUpdated Sep 27, 2026Shares Short
20.45MSharesUpdated Sep 27, 2026Short Ratio
5.72daysvs all stocks
Short % of Shares Outstanding
17.32%vs all stocks
% Held by Insiders
11.21%vs all stocks
% Held by Institutions
96.63%vs all stocks
Total Cash (MRQ)
267.87MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.77USDUpdated Sep 27, 2026Total Debt (MRQ)
297.04MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
24.30xvs Biotechnology peers
Current Ratio (MRQ)
4.73xvs Biotechnology peers
Book Value per Share (MRQ)
0.0810USDUpdated Sep 27, 2026Total Assets
451.45MUSDvs all stocks (USD)
Total Current Assets
368.33MUSDFY2025 · Dec 31, 2025Total Liabilities
399.38MUSDFY2025 · Dec 31, 2025Total Non-current Assets
83.12MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
283.44MUSDFY2025 · Dec 31, 2025Total Current Liabilities
115.93MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
229.96MUSDFY2025 · Dec 31, 2025Other Short-term Investments
89.18MUSDFY2025 · Dec 31, 2025Accounts Payable
11.64MUSDFY2025 · Dec 31, 2025Short-term Debt
5.76MUSDFY2025 · Dec 31, 2025Other Current Liabilities
42.71MUSDFY2025 · Dec 31, 2025Long-term Debt
278.86MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
4.58MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.93BUSDFY2025 · Dec 31, 2025Retained Earnings
-2.08BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
52.07MUSDvs all stocks (USD)
52-Week Low
7.48USDUpdated Sep 27, 202652-Week High
18.57USDUpdated Sep 27, 202652-Week Change
-11.39%vs all stocks
Beta
3.17xvs all stocks
50-Day MA
14.29USDUpdated Sep 27, 2026200-Day MA
11.99USDUpdated Sep 27, 2026Avg 10-Day Volume
3.23MSharesUpdated Sep 27, 2026Avg 30-Day Volume
3.46MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-4.55USDUpdated Sep 27, 2026Other Income / Expense
8.00MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -799.5%, lower than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: -7.99Industry median: -0.24Industry P5: -1.76Peers compared: 193
Debt-to-equity is 24.3×, higher than 95% of its Biotechnology peers (median 0.12×)Significant
Debt-to-equity: 24.30Industry median: 0.12Industry P95: 2.33Peers compared: 193
Price-to-book is 160.37×, higher than 95% of its Biotechnology peers (median 4.62×)Significant
Price-to-book: 160.37Industry median: 4.62Industry P95: 31.44Peers compared: 193
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 267,866,000Total Debt (USD): 297,035,008Debt-to-Equity: 24.30
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Levered free cash flow is -$256.22M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -256,219,056Global P5: -202,685,365.334
Market cap is $1.96B, above the global median of $1.18BNotable
Market cap (USD): 1,962,058,715Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sarepta Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Agios Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zymeworks Inc.
Tier 1ProductionApproval-Gated PipelineRule
Galapagos NV
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Urogen Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule